|  |  |
| --- | --- |
| **Supplementary file 1 - Table 1.** |  |
| Study Groups | **Healthy Control** | **Early HIV-1 infection** | **HIV-1 on ART** | ƥ |
| HC | Ei | S |
| Number of subjects  | 24 | 24 | 24 |  |
| Gender (M/F) [n (%)] | 16/8 (67/33%) | 23/1 (96/4%) | 18/6 (75/25%) | 0.091 |
| Weeks since seroconversion [median (IQR)] | - | 1.3 (0.77 - 17.8) | - | - |  |
| Number of samples  | 24 | 24 | 24 (S1) | 24 (S2) |  |
| Age at sample (years) [median (IQR)] | 43.1 (38.1 - 52.5) | 43.3 (41.8 - 46.2) | 40.6 (35.1 - 44.7) | 50.0 (43.7 - 55.1) | 0.0035 |
|  |  |  |  |  |
| CD4+ T-cell counts at sample per mm3 [median (IQR)] | - | 630 (557 - 757.3) | 573 (464 - 992) | 910 (799.8 - 1111) | 0.0001 |
|  |  |  |  |  |  |
| Years undetectable at sample on ART[median (IQR)] | - | 0.0 | 2.2 (1.8 - 2.8) | 10.1 (7.4 - 12.9) | <0.0001 |
| VL log copies/ml at sample [median (IQR)] | - | 4.5 (4.3 - 5.1) | undetectable | undetectable | <0.0001 |
| Abbreviations: IQR, interquartile range; P-values were calculated using Kruskal-Wallis test (Dunn´s correction) or X2-test. |

**The epidemiological and clinical characteristics of the study groups.**

Table showing the clinical data and biological sample availability from study groups, healthy controls (HC), PLWH in early HIV-1 infection (Ei), and PLWH on fully suppressive ART (S) in S1 and S2 time points. Ei individuals were defined in a window of 1.3 (0.77 - 17.8) weeks after seroconversion in the absence of ART. PLWH on fully suppressive ART (S) in S1 and S2 time points were treated mainly with a combination of NNRTI and NRTI for more than ten years with sustained virological suppression (<50 HIV-1-RNA copies/ml). We excluded individuals with integrase inhibitors, ART as monotherapy, and treatments with mitochondrial toxicity, including Trizivir, d4T, ddI, AZT and blips over the ART period (S1- S2) to ensure homogeneous treatment over time. All groups were balanced by age to the S2 samples to avoid confounding effects on IR expression.